2m 2m 2m 2m 2m 2m 2m
Regeneron Pharma (REGN)
NASDAQ
$617.99+$5.49 (+0.90%)
Price as of Jun 23, 2026 4:14 PM EDT- $63.1BMarket Cap
- 20.30%1-Year Change
- BiotechnologyIndustry
Regeneron Pharma (REGN)
$617.99+$5.49 (+0.90%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 6.3B -55.58% | 14.2B +8.27% | 13.1B +7.76% | 12.2B -24.26% | |
Cost of Revenue | 1.1B -42.11% | 2.0B +8.52% | 1.8B +16.37% | 1.6B -35.98% | |
Gross Profit | 5.2B -57.75% | 12.2B +8.23% | 11.3B +6.49% | 10.6B -22.16% | |
Sales and Marketing Expense | 2.7B -8.61% | 3.0B +12.28% | 2.6B +24.36% | 2.1B +15.95% | |
Research and Development Expense | -5.9B +13.99% | -5.1B +15.61% | -4.4B +23.56% | -3.6B +23.53% | |
Depreciation and Amortization Expense | 543.7M +12.59% | 482.9M +14.70% | 421.0M +23.32% | 341.4M +19.29% | |
Total Operating Expenses | 10.8B +5.42% | 10.2B +12.58% | 9.1B +22.01% | 7.4B +4.34% | |
Operating Profit | 3.6B -10.34% | 4.0B -1.39% | 4.0B -14.60% | 4.7B -47.03% | |
Interest Income | 716.8M +0.76% | 711.4M +43.46% | 495.9M +209.74% | 160.1M N/A | |
Interest Expense | -44.4M 0.00% | -44.4M -39.18% | -73.0M +22.90% | -59.4M +3.66% | |
Interest Income and Expense and Net | 672.4M +0.81% | 667.0M +57.72% | 422.9M +319.96% | 100.7M +275.74% | |
Total Nonoperating Income and Expense | 1.7B +109.43% | 789.2M +418.53% | 152.2M +26.94% | 119.9M -68.36% | |
Income before Taxes | 5.2B +9.43% | 4.8B +13.83% | 4.2B -13.57% | 4.9B -47.90% | |
Income Taxes | 725.8M +97.60% | 367.3M +49.49% | 245.7M -52.79% | 520.4M -58.38% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | 4.5B +2.09% | 4.4B +11.61% | 4.0B -8.87% | 4.3B -46.28% | |
Net Income from Continuing Operations Applicable to Common | 5.2B +9.43% | 4.8B +13.83% | 4.2B -13.57% | 4.9B -47.90% | |
Basic EPS and Net Income | 43.07 +5.31% | 40.90 +10.39% | 37.05 -8.54% | 40.51 -46.98% | |
Diluted EPS and Net Income | 41.48 +8.19% | 38.34 +10.27% | 34.77 -9.03% | 38.22 -46.89% | |
Basic Weighted Average Shares | 104.6M -3.06% | 107.9M +1.12% | 106.7M -0.37% | 107.1M +1.32% | |
Diluted Weighted Average Shares | 108.6M -5.65% | 115.1M +1.23% | 113.7M +0.18% | 113.5M +1.16% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 3.1B +25.32% | 2.5B -8.86% | 2.7B -12.10% | 3.1B +7.63% | |
Short-Term Investments | 5.5B -15.90% | 6.5B -19.60% | 8.1B +75.02% | 4.6B +65.05% | |
Cash and Cash Equivalents and Short-Term Investments | 8.6B -4.52% | 9.0B -16.90% | 10.8B +40.07% | 7.7B +35.96% | |
Total Current Assets | 18.0B -3.42% | 18.7B -4.20% | 19.5B +22.63% | 15.9B +13.34% | |
Accumulated Depreciation | 2.6B +14.32% | 2.3B +15.57% | 2.0B +18.55% | 1.7B +19.39% | |
Property and Plant and Equipment and Net | 5.1B +11.32% | 4.6B +10.93% | 4.1B +10.19% | 3.8B +8.06% | |
Total Long-Term Assets | 1.8B +60.32% | 1.1B +155.80% | 444.1M +32.02% | 336.4M +50.99% | |
Total Assets | 40.6B +7.41% | 37.8B +14.15% | 33.1B +13.23% | 29.2B +14.86% | |
Income Taxes Payable | 351.3M +64.77% | 213.2M N/A | N/A N/A | 300,000 -99.91% | |
Total Short-Term Debt | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Total Current Liabilities | 4.4B +10.75% | 3.9B +15.22% | 3.4B +8.98% | 3.1B -20.12% | |
Total Long-Term Debt | 2.0B +0.08% | 2.0B +0.08% | 2.0B +0.08% | 2.0B +0.07% | |
Total Long-Term Liabilities | 2.0B +28.47% | 1.6B +83.98% | 854.1M +33.87% | 638.0M -6.20% | |
Total Liabilities | 9.3B +10.66% | 8.4B +18.27% | 7.1B +8.50% | 6.6B -1.73% | |
Retained Earnings | 35.8B +13.02% | 31.7B +16.19% | 27.3B +16.96% | 23.3B +22.87% | |
Total Stockholders Equity | 31.3B +6.48% | 29.4B +13.02% | 26.0B +14.60% | 22.7B +20.75% | |
Total Shares Outstanding | 1.8M -98.68% | 136.0M +23.90% | 109.8M +0.40% | 109.3M +0.72% | |
Cash Flow | |||||
Cash from Operating Activities | 5.0B +12.63% | 4.4B -3.78% | 4.6B -8.39% | 5.0B -29.18% | |
Capital Expenditures | 898.4M +18.85% | 755.9M +5.19% | 718.6M +21.78% | 590.1M +6.92% | |
Cash from Investing Activities | -629.1M -74.51% | -2.5B -22.51% | -3.2B -15.84% | -3.8B -29.72% | |
Dividends Paid | 370.3M N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -3.7B +68.84% | -2.2B +22.93% | -1.8B +77.41% | -1.0B +0.32% | |
Financials Ratio | |||||
Gross Margin | 81.92% -4.88% | 86.13% -0.04% | 86.16% -1.17% | 87.18% +2.77% | |
Operating Margin | 56.71% +101.82% | 28.10% -8.93% | 30.85% -20.75% | 38.93% -30.07% | |
Return on Assets | 11.50% -7.66% | 12.46% -1.85% | 12.69% -20.05% | 15.88% -58.12% | |
Return on Equity | 14.87% -6.81% | 15.95% -1.88% | 16.26% -22.37% | 20.94% -61.37% | |
Revenue Growth | -55.58% -772.01% | 8.27% +6.61% | 7.76% +131.98% | -24.26% -127.21% | |
Current Ratio | 4.13 -12.80% | 4.73 -16.85% | 5.69 +12.53% | 5.06 +41.88% | |
Cash Ratio | 0.71 +13.16% | 0.63 -20.90% | 0.80 -19.34% | 0.99 +34.74% | |
Debt-to-Equity Ratio | 0.06 -6.07% | 0.07 -11.40% | 0.08 -12.70% | 0.09 -17.16% | |
Debt-to-Assets Ratio | 0.05 -6.84% | 0.05 -12.19% | 0.06 -11.65% | 0.07 -12.85% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow